OSAMAH TAWFIQ KHOJAH

Prof. Dr. OSAMAH TAWFIQ KHOJAH

orcid
Motivated Healthcare Leader

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
FKFizza Khalid
Fizza Khalid
WAWael Jumah Aljohani
Wael Jumah Aljohani
AAAdeel Akram
Adeel Akram
ABAbdullah Bukhari
Abdullah Bukhari
OSAMAH TAWFIQ KHOJAHOSAMAH TAWFIQ KHOJAH
OSAMAH TAWFIQ KHOJAH
Urinary tract infections (UTIs) represent one of the most frequent bacterial infections worldwide, with Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) as the predominant uropathogens. The emergence of extended-spectrum β-lactamase (ESBL)-producing Enterobacterales has severely limited treatment options, making regional surveillance crucial. This study aimed to determine the prevalence of uropathogens, assess antimicrobial resistance patterns, and evaluate the burden of ESBL-producing organisms among patients presenting with suspected UTIs in a tertiary care hospital in Riyadh. We conducted a retrospective analysis of 19,556 urine cultures from a tertiary care hospital in Riyadh, Saudi Arabia, between January and December 2024. Of these, 2629 (13.4%) cultures showed significant bacterial growth, predominantly in females (83.2%) and in the 16–30 year age group. E. coli accounted for 65.9% of isolates, followed by K. pneumoniae (16.8%). ESBL production was detected in 28.5% of E. coli and Klebsiella isolates. ESBL producers exhibited complete resistance to third-generation cephalosporins and β-lactam/β-lactamase inhibitor combinations, whereas carbapenems, aminoglycosides, and fosfomycin maintained high efficacy. Resistance to ciprofloxacin and co-trimoxazole was widespread in both ESBL and non-ESBL isolates. Additionally, vancomycin-resistant enterococci (7%), methicillin-resistant Staphylococcus aureus (2%), and carbapenem-resistant Enterobacterales (0.9%) were found. These findings highlight the escalating burden of ESBL-associated UTIs and underscore the urgent need for strengthened antimicrobial stewardship, continuous surveillance, and optimized empirical therapy to mitigate the impact of multidrug-resistant uropathogens in clinical practice.

2 October 2024 in Microbiology Research
Verified
Journal Article
Open access
PDF file
FKFizza Khalid
Fizza Khalid
CPChristy Poulose
Christy Poulose
DFDalal Farah Mousa Farah
Dalal Farah Mousa Farah
AMAbid Mahmood
Abid Mahmood
AEAzza Elsheikh
Azza Elsheikh
OSAMAH TAWFIQ KHOJAHOSAMAH TAWFIQ KHOJAH
OSAMAH TAWFIQ KHOJAH
The long history and extensive use of antibiotics have caused resistant bacterial pathogens to emerge, increasing mortality and morbidity. The current study was designed to see the prevalence of aerobic bacterial isolates with their antimicrobial resistance pattern from out- and inpatients requested for wound or pus culture. Retrospective study conducted at a tertiary care hospital in central Riyadh from January 2023 to December 2023. Samples were collected and inoculated onto the appropriate media following standard guidelines. Bacterial pathogens were identified by the Vitek2 compact system. Antimicrobial susceptibility was tested using the Kirby–Bauer disk diffusion method as well as by MIC determination through the Vitek2 compact. A total of 1186 subjects were included in the study with a bacterial isolation rate of 691 (58.3%). Out of these, 155 positive cultures had incomplete information or anaerobic or fungal growth and were excluded from the study. With a slight female predominance (54.9%), the majority of subjects (72.2%) were outpatients, and over half of the isolates (55.2%) were Gram-positive. The most common isolate was Staphylococcus spp. (44.4%), followed by E. coli (13.6%) and P. aeruginosa (12.9%). The highest resistance was reported against penicillin followed by fusidic acid against Gram-positive bacteria. Methicillin-resistant Staphylococcus aureus (MRSA) was detected in 40.5% of Staphylococcus aureus (S. aureus) isolates. Amikacin was the most susceptible antibiotic against all Gram-negative isolates. MDR Gram-negative bacteria accounted for 51.9% of wound infection isolates (95% CI: 45.95 to 58.33) while 6.3% (95% CI: 4.39 to 8.86) were XDR (nonsusceptibility to at least one agent in all but two or fewer antimicrobial categories). A high prevalence of bacterial isolates, with S. aureus as the predominant pathogen, showed high rates of multidrug resistance. This highlights the importance of monitoring antibiotic choices for prophylaxis and treatment in the study area.

10 October 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
Mariam Mohammed Ali AlEissaMariam Mohammed Ali AlEissa
Mariam Mohammed Ali AlEissa
AAAhdab Alsaieedi
Ahdab Alsaieedi
RAReema Alduaiji
Reema Alduaiji
FAFahad Almsned
Fahad Almsned
YAYousif AlDossary
Yousif AlDossary
Abdullah M. AsiriAbdullah M. Asiri
Abdullah M. Asiri
Background: In the Kingdom of Saudi Arabia, various COVID-19 vaccines were administered during the pandemic. However, region-specific real-word comparative data on their immunogenicity remain limited. This study aimed to assess the serological responses to Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), and AstraZeneca (ChAdOx1 nCoV-19) vaccines in a diverse population living in KSA. Methods: This observational study included 236 adults recruited from vaccination sites in Riyadh. Participants provided serum samples at predefined intervals: before the first dose, after the first dose, after the second dose, and post-vaccination infection (if applicable). IgG and neutralising antibodies were quantified using ELISA assays. Demographic and vaccination data, and their associations with antibody responses, were evaluated. Results: At baseline, 75.4% of participants were positive for SARS-CoV-2 IgG, suggesting high prior exposure. Marked incremental increases in IgG levels were observed after each vaccine dose. Both Moderna and Pfizer elicited stronger responses, with Pfizer inducing the strongest early response and Moderna achieving the highest overall titres. Among IgG-positive individuals, neutralising antibodies were detected in 98.1%. There were no statistically significant differences by age or gender, although males tended to show higher mean titres. Heterologous vaccine schedules induced comparable or enhanced immunogenicity relative to homologous schedules, supporting their use in flexible immunisation strategies. Conclusions: All COVID-19 vaccines administered in Saudi Arabia elicited robust antibody responses, particularly the mRNA-based vaccines. Our findings support their continued use and justify varied vaccination approaches, including mix-and-match booster strategies, to enhance community immunity.

1 October 2020 in JMIR Research Protocols
Verified
Journal Article
Open access
MAMohammed Abdul Hameed Albelowi
Mohammed Abdul Hameed Albelowi
SZSyed Ziauddin A Zaidi
Syed Ziauddin A Zaidi
NANawal AlShehry
Nawal AlShehry
AAAhmed AlAskar
Ahmed AlAskar
Abdul Rehman Zia ZaidiAbdul Rehman Zia Zaidi
Abdul Rehman Zia Zaidi
HAHani Al-Hashmi
Hani Al-Hashmi
Background: The COVID-19 pandemic is expected to cause significant morbidity and mortality. The development of an effective vaccine will take several months to become available, and its affordability is unpredictable. Transfusion of convalescent plasma (CP) may provide passive immunity. Based on initial data from China, a group of hematologists, infectious disease specialists, and intensivists drafted this protocol in March 2020. Objective: The aim of this study is to test the feasibility, safety, and efficacy of CP in treating patients with COVID-19 across Saudi Arabia. Methods: Eligible patients with COVID-19 will be recruited for CP infusion according to the inclusion criteria. As COVID-19 has proven to be a moving target as far as its management is concerned, we will use current definitions according to the Ministry of Health (MOH) guidelines for diagnosis, treatment, and recovery. All CP recipients will receive supportive management including all available recommended therapies according to the available MOH guidelines. Eligible CP donors will be patients with COVID-19 who have fully recovered from their disease according to MOH recovery criteria as detailed in the inclusion criteria. CP donors have to qualify as blood donors according to MOH regulations except for the history of COVID-19 in the recent past. We will also test the CP donors for the presence of SARS-CoV-2 antibodies by a rapid test, and aliquots will be archived for future antibody titration. Due to the perceived benefit of CP, randomization was not considered. However, we will compare the outcome of the cohort treated with CP with those who did not receive CP due to a lack of consent or lack of availability. In this national collaborative study, there is a likelihood of not finding exactly matched control group patients. Hence, we plan to perform a propensity score matching of the CP recipients with the comparator group patients for the major characteristics. We plan to collect demographic, clinical, and laboratory characteristics of both groups and compare the outcomes. A total sample size of 575 patients, 115 CP recipients and 460 matched controls (1:4 ratio), will be sufficient to detect a clinically important hospital stay and 30-day mortality difference between the two groups with 80% power and a 5% level of significance. Results: At present, patient recruitment is still ongoing, and the interim analysis of the first 40 patients will be shared soon. Conclusions: In this paper, we present a protocol for a national collaborative multicenter phase II study in Saudi Arabia for assessing the feasibility, safety, and potential efficacy of CP in treating patients with severe COVID-19. We plan to publish an interim report of the first 40 CP recipients and their matched comparators soon.

1 February 2025 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
RAReham Alahmadi
Reham Alahmadi
MAMaaweya Elaeed Awadalla
Maaweya Elaeed Awadalla
NMNajat Marraiki
Najat Marraiki
MAMohammed Alswayyed
Mohammed Alswayyed
HAHajar Alshehri
Hajar Alshehri
Bandar AlosaimiBandar Alosaimi
Bandar Alosaimi
Background: Base of tongue squamous cell carcinoma (BOTSCC) is a prevalent and aggressive form of oral cancer, often associated with poor patient outcomes. The tumor microenvironment (TME) of HPV-positive BOTSCC is critical in influencing cancer progression and treatment response. Objective: This study aims to analyze the TME of HPV-positive BOTSCC by examining the expression of key genes involved in various biological processes. Methods: We utilized the RT2 Profiler PCR Array to quantify the expression of 168 genes related to inflammation, immunity, oncogenesis, tumor suppression, apoptosis, and angiogenesis. Enrichment analysis of cancer hallmarks was performed on all upregulated genes. Additionally, we investigated the correlation between the expression levels of the ten most highly upregulated genes and survival prognosis in HPV-associated BOTSCC patients. Results: Our analysis revealed dysregulation of 42 genes associated with tumor-immune interactions, with 20 genes upregulated and 22 downregulated. Furthermore, we identified 64 genes linked to cancer development, with 33 upregulated and 31 downregulated. High-risk HPV (hr-HPV) genotypes were found in 81% of patients, predominantly HPV-35 and HPV-16. Conclusion: This study highlights the complexity of the HPV-positive BOTSCC TME, underscoring the need for further research into molecular pathways and immune interactions to identify new therapeutic targets for improved cancer treatment. Plain Language Summary: Base of tongue squamous cell carcinoma (BOTSCC) is a highly aggressive form of oral cancer often associated with poor prognosis. This study focuses on the tumor microenvironment (TME) in HPV-positive BOTSCC, investigating the expression of 168 genes implicated in anti-inflammatory, anti-tumor, and other critical biological functions. Among these, 64 genes associated with cancer growth and regulation and 42 genes involved in tumor-immune interactions were identified as dysregulated. The high-risk HPV-35 strain emerged as the most prevalent subtype. Further analysis explored the impact of the most significantly upregulated genes on immune cell dynamics within the tumor and patient survival outcomes. These findings provide novel insights into the complex TME of HPV-positive BOTSCC, underscoring the importance of further research to delineate key molecular pathways and identify potential therapeutic targets.

21 April 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
FKFizza Khalid
Fizza Khalid
AAAhmed Alzahrani
Ahmed Alzahrani
HMHilal Mohammed
Hilal Mohammed
AGAymen Khalaf Allah Gamma
Aymen Khalaf Allah Gamma
MHMohamed Elhadi Hassan
Mohamed Elhadi Hassan
OSAMAH TAWFIQ KHOJAHOSAMAH TAWFIQ KHOJAH
OSAMAH TAWFIQ KHOJAH
Background: Turnaround time (TAT) is a key performance indicator in clinical microbiology, particularly for urine cultures, which represent a high-volume workload and directly impact antimicrobial stewardship. Methods: This retrospective observational study compared urine culture TAT before (2023, manual workflow) and after (2025, total laboratory automation using WASPLab™) implementation in a high-volume reference laboratory. A total of 16,210 cultures in 2023 and 60,474 in 2025 were included. TAT was defined as the time from laboratory receipt to final report validation. Results: Implementation of total laboratory automation significantly reduced median TAT for both negative cultures (from 49.68 to 34.38 h) and positive cultures (from 50.42 to 34.62 h) (p < 0.001). In addition, variability in reporting times decreased, indicating improved consistency. Laboratory productivity increased from 2316 to 7559 cultures per full-time equivalent, representing a 3.26-fold improvement. Conclusions: Total laboratory automation significantly improved the speed and consistency of urine culture reporting, supporting enhanced laboratory efficiency and facilitating timely clinical decision-making.